Mark & Steven Bornfeld wrote:
rupali wrote:
please visit the following link:
http://www.biospectrumindia.com/content/research/10504112.asp
-
The new heart cells were obtained by injecting stem cells in the
affected region (comprising of dead muscle cells) of the heart. These
stem cells then differentiated to form new heart cells. It is thus
possible to obtain differentiated heart cells.
Considering the fact that the heart cells are of a uniform type they
might probably be easier to regenerate theoretically. Nevertheless it
proves that it is possible to regenerate cells of a partially dead or
necrosed organ presumably such as pulp especially considering the cells
present in the pulpal tissue. Establishing the nervous supply may prove
challenging though.....but possible.
It would be nice to know just what tissue was regenerated--myocardium?
Endocardium? Valvular structures?
Steve
--
Mark & Steven Bornfeld DDS
http://www.dentaltwins.com
Brooklyn, NY
718-258-5001
Recently published at AHA, 2005
REPAIR-AMI: Reinfusion of Enriched Progenitor Cells and Infarct
Remodeling in Acute Myocardial Infarction
Can the infusion of autologous bone marrow-derived progenitor cells
following successful reperfusion in AMI patients prevent the onset of
post-MI heart failure?
Presenter: Volker Schächinger, MD (J.W. Goethe University, Frankfurt,
Germany)
Acute myocardial infarction (AMI) can lead to infarct expansion,
chronic left ventricular (LV) dilatation, and, eventually, chronic
heart failure. Postinfarction heart failure remains a major challenge
for the clinical cardiologist despite "optimal" therapy. For many
years, there has been ample research conducted to find ways to diminish
the development of heart failure and to enhance myocardial recovery
following AMI. Small phase 1 trials have suggested that the
intracoronary application of mononuclear progenitor cells derived from
the bone marrow may be safe and may contribute to functional
regeneration of the infarcted myocardium.
Conclusions:
Intracoronary infusion of bone marrow-derived mononuclear cells in
patients with reperfused AMI:
-Is associated with improved global LV contractile function
-Preferentially improves LV function in patients with the most severely
depressed contractility after AMI
-Prevents LV ESV expansion within 4 months of therapy
-Holds great promise to limit the development of postinfarction heart
failure
******************************************************************************
AMI = acute mycardial infarction
LV = left ventricular
ESV = end systolic volume (an expansion in ESV indicates remodelling
---> BAD!)
